التهاب المفاصل الصدفي المحوري عندما تفشل مضادات الالتهاب غير الستيرويدية في السيطرة على الأعراض

References

• In patients with clinically relevant axial disease with an insufficient response to NSAIDs, therapy with an IL-17A inhibitor, a TNF inhibitor, an IL-17 A/F inhibitor or a JAKi should be considered.
• Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.